These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 21649738)
1. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Frey K; Fiechter M; Schwager K; Belloni B; Barysch MJ; Neri D; Dummer R Exp Dermatol; 2011 Aug; 20(8):685-8. PubMed ID: 21649738 [TBL] [Abstract][Full Text] [Related]
2. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Schliemann C; Wiedmer A; Pedretti M; Szczepanowski M; Klapper W; Neri D Leuk Res; 2009 Dec; 33(12):1718-22. PubMed ID: 19625084 [TBL] [Abstract][Full Text] [Related]
3. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Pedretti M; Rancic Z; Soltermann A; Herzog BA; Schliemann C; Lachat M; Neri D; Kaufmann PA Atherosclerosis; 2010 Feb; 208(2):382-9. PubMed ID: 19699478 [TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Pedretti M; Soltermann A; Arni S; Weder W; Neri D; Hillinger S Lung Cancer; 2009 Apr; 64(1):28-33. PubMed ID: 18799229 [TBL] [Abstract][Full Text] [Related]
5. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Brack SS; Silacci M; Birchler M; Neri D Clin Cancer Res; 2006 May; 12(10):3200-8. PubMed ID: 16707621 [TBL] [Abstract][Full Text] [Related]
6. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. Kääriäinen E; Nummela P; Soikkeli J; Yin M; Lukk M; Jahkola T; Virolainen S; Ora A; Ukkonen E; Saksela O; Hölttä E J Pathol; 2006 Oct; 210(2):181-91. PubMed ID: 16924594 [TBL] [Abstract][Full Text] [Related]
7. Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. Dang C; Gottschling M; Roewert J; Forschner T; Stockfleth E; Nindl I Br J Dermatol; 2006 Oct; 155(4):763-70. PubMed ID: 16965426 [TBL] [Abstract][Full Text] [Related]
8. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Schwager K; Villa A; Rösli C; Neri D; Rösli-Khabas M; Moser G Head Neck Oncol; 2011 May; 3():25. PubMed ID: 21548989 [TBL] [Abstract][Full Text] [Related]
9. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Kageshita T; Ishihara T; Campoli M; Ferrone S Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896 [TBL] [Abstract][Full Text] [Related]
10. Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Ambort D; Brellier F; Becker-Pauly C; Stöcker W; Andrejevic-Blant S; Chiquet M; Sterchi EE Matrix Biol; 2010 Jan; 29(1):31-42. PubMed ID: 19748582 [TBL] [Abstract][Full Text] [Related]
11. Analysis of combinatorial variability reveals selective accumulation of the fibronectin type III domains B and D of tenascin-C in injured brain. Dobbertin A; Czvitkovich S; Theocharidis U; Garwood J; Andrews MR; Properzi F; Lin R; Fawcett JW; Faissner A Exp Neurol; 2010 Sep; 225(1):60-73. PubMed ID: 20451518 [TBL] [Abstract][Full Text] [Related]
12. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459 [TBL] [Abstract][Full Text] [Related]
14. Up-regulation of growth hormone receptor immunoreactivity in human melanoma. Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136 [TBL] [Abstract][Full Text] [Related]
15. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. Franz M; Brehm BR; Richter P; Gruen K; Neri D; Kosmehl H; Hekmat K; Renner A; Gummert J; Figulla HR; Berndt A J Mol Histol; 2010 Feb; 41(1):39-50. PubMed ID: 20232238 [TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291 [TBL] [Abstract][Full Text] [Related]
17. Expression of tenascin-C splice variants by human skin cells. Latijnhouwers MA; de Jongh GJ; Bergers M; de Rooij MJ; Schalkwijk J Arch Dermatol Res; 2000 Sep; 292(9):446-54. PubMed ID: 11000288 [TBL] [Abstract][Full Text] [Related]
18. Tenascin-C in primary malignant melanoma of the skin. Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480 [TBL] [Abstract][Full Text] [Related]
19. Opposite effect of fluticasone and salmeterol on fibronectin and tenascin-C expression in primary human lung fibroblasts. Degen M; Goulet S; Ferralli J; Roth M; Tamm M; Chiquet-Ehrismann R Clin Exp Allergy; 2009 May; 39(5):688-99. PubMed ID: 19309351 [TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Kageshita T; Yoshii A; Kimura T; Kuriya N; Ono T; Tsujisaki M; Imai K; Ferrone S Cancer Res; 1993 Oct; 53(20):4927-32. PubMed ID: 8104688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]